Brain Natriuretic Peptide (BNP): What It Is and Why It Matters

Key Takeaways

• What it measures: Ventricular wall stress; levels rise when the heart is under increased hemodynamic load.
• Typical reference range: Below 100 pg/mL for BNP in adults (general); NT-proBNP below 125 pg/mL for non-acute presentations. Ranges vary substantially by age, sex, and lab platform.
• Sample type: EDTA plasma (purple-top tube) for BNP; serum or plasma for NT-proBNP depending on assay.
• Fasting required: No.
• When providers order it: Shortness of breath, suspected heart failure, dyspnea workup, cardiac stress monitoring.
• Test frequency: Ordered as needed; may be repeated during heart failure management or after treatment changes.
• Key confounder: Obesity is associated with lower BNP levels; a normal or low BNP in a patient with obesity and cardiac symptoms should not be interpreted as ruling out cardiac stress.

What Brain Natriuretic Peptide Is and Where It Comes From

BNP (B-type natriuretic peptide, also called brain natriuretic peptide) is a 32-amino-acid cardiac hormone released by the ventricular myocardium in response to increased wall stress or volume overload. It acts on natriuretic peptide receptor type A (NPR-A) in the kidneys and vasculature to promote sodium excretion, increase urine output, and cause vasodilation — a compensatory response designed to reduce cardiac workload. In clinical medicine, its main use is as a measurable biomarker of cardiac stress, with levels reflecting the degree of hemodynamic burden on the heart.

The name requires an immediate clarification. BNP was first isolated from porcine brain tissue by Sudoh and colleagues, whose landmark 1988 paper in Nature described a new 26-amino-acid natriuretic peptide extracted from pig brain, leading to the name "brain natriuretic peptide." Subsequent research established that this was a tissue-discovery artifact: in humans, BNP is produced predominantly by the heart, not the brain. Hosoda and colleagues, in a 1991 paper in Hypertension, demonstrated that BNP gene expression in the human heart is concentrated in the ventricles, not the atria, and not in neural tissue. The name persists in clinical usage, but "B-type natriuretic peptide" and the abbreviation BNP are now the preferred designators in clinical guidelines.

BNP is synthesized as a 134-amino-acid precursor (pre-proBNP), cleaved in cardiomyocytes to a 108-amino-acid prohormone (proBNP), and then processed by corin — a transmembrane serine protease on the cardiomyocyte surface — into the 32-amino-acid active BNP and the 76-amino-acid N-terminal fragment (NT-proBNP). Wu and colleagues, in a 2009 review in Kidney International, described corin as a key convertase in natriuretic peptide activation, best characterized for pro-ANP processing, providing the mechanistic foundation for the biosynthesis pathway. Both BNP and NT-proBNP are released into circulation, but they have different half-lives and different clinical reference ranges.

BNP Reference Ranges

Reference values for BNP and NT-proBNP differ substantially depending on the assay platform, clinical context (acute vs. non-acute), and patient characteristics including age and sex. The following represent commonly used population-derived reference intervals from the clinical literature.

• Adults (general), BNP — Rule-out threshold (non-acute HF): Below 35 pg/mL per 2021 ESC Guidelines
• Adults (general), BNP — Acute dyspnea rule-in (higher HF probability): Above 400 pg/mL
• Adults (general), BNP — Acute setting rule-out: Below 100 pg/mL
• Adults (general), NT-proBNP — Rule-out (non-acute): Below 125 pg/mL
• Adults under 50, NT-proBNP — Acute HF rule-in: Above 450 pg/mL
• Adults 50 to 75, NT-proBNP — Acute HF rule-in: Above 900 pg/mL
• Adults over 75, NT-proBNP — Acute HF rule-in: Above 1,800 pg/mL

Reference ranges vary by laboratory and individual. The values above represent guideline-derived clinical reference intervals from McDonagh and colleagues, published in the European Heart Journal in 2021, and from the age-stratified ICON study data. These are not diagnostic thresholds — your provider will interpret your specific result alongside symptoms, medical history, and other test findings.

How BNP Works in the Body

BNP is part of the natriuretic peptide family, which functions as a counterregulatory system opposing the water-retaining and vasoconstricting effects of the renin-angiotensin-aldosterone system (RAAS). When ventricular cardiomyocytes detect increased wall tension — from elevated filling pressures, volume overload, elevated blood pressure, or ischemia — they respond by synthesizing and releasing BNP and its co-secreted fragment, NT-proBNP.

Receptor binding and downstream signaling

BNP binds primarily to natriuretic peptide receptor type A (NPR-A), a membrane-bound guanylyl cyclase. Receptor activation generates cyclic guanosine monophosphate (cGMP), which mediates the downstream physiological effects: vasodilation of arteries and veins, inhibition of aldosterone secretion, suppression of renin release, and promotion of sodium excretion (natriuresis) and urine output (diuresis). Potter and colleagues, in a highly cited 2006 review in Endocrine Reviews, provided detailed coverage of cGMP-dependent signaling downstream of NPR-A. A second receptor, NPR-C, functions as a clearance receptor — binding and internalizing natriuretic peptides without signaling, effectively regulating their circulating concentrations. Potter and colleagues, in a 2009 handbook chapter, reviewed natriuretic peptide structures, receptors, and physiological functions across the full family.

Physiological role in heart failure

In the context of heart failure, BNP secretion is amplified by the sustained hemodynamic burden on the ventricles. The resulting elevated BNP represents both a compensatory attempt to reduce preload and afterload and a measurable marker of the degree of that burden. Volpe and colleagues, in a 2016 review in Clinical Science, reviewed the molecular basis of the natriuretic peptide system in heart failure through to clinical treatment implications, establishing BNP as a physiological actor in the disease process as well as a diagnostic marker. Kuwahara, writing in Pharmacology and Therapeutics in 2021, provided a deep mechanistic review of the natriuretic peptide system in heart failure, including the diagnostic and therapeutic implications of elevated levels.

Half-life and clearance

Active BNP has a plasma half-life of approximately 20 minutes, cleared by NPR-C internalization and neprilysin (neutral endopeptidase) degradation. NT-proBNP has a longer half-life of 1 to 2 hours and is cleared primarily through renal filtration, explaining why NT-proBNP is more strongly elevated in chronic kidney disease than BNP. Michel and colleagues, in a 2022 Circulation Research paper, showed how proANP metabolism informs sacubitril/valsartan mode of action, illustrating how pharmacological inhibition of neprilysin alters the clearance of natriuretic peptides — with the critical implication that BNP levels rise in patients on sacubitril/valsartan even as cardiac function improves.

BNP vs. NT-proBNP: Key Differences

Both markers are released simultaneously from the same precursor, but they differ in ways that affect how results are interpreted and which assay is more appropriate in different clinical contexts.

• BNP (active hormone) — Half-life: Approximately 20 minutes; cleared by neprilysin and NPR-C
• NT-proBNP (inactive fragment) — Half-life: 1 to 2 hours; cleared primarily by renal filtration
• BNP — Sacubitril/valsartan effect: Rises during sacubitril/valsartan treatment because neprilysin inhibition blocks BNP degradation — making BNP unreliable for monitoring in treated patients
• NT-proBNP — Sacubitril/valsartan effect: Falls during treatment as expected, remaining a reliable monitoring marker
• BNP — Reference range example: Below 100 pg/mL (acute rule-out)
• NT-proBNP — Reference range example: Below 300 pg/mL (acute rule-out); age-stratified for rule-in (450/900/1,800 pg/mL)

Yeo and colleagues, in a 2005 Journal of Cardiac Failure study, directly compared Elecsys NT-proBNP and BNP assays, documenting analytical and clinical differences that explain why the two tests cannot be used interchangeably and why each has distinct reference intervals. Masson and colleagues, in the Val-HeFT comparative analysis published in Clinical Chemistry in 2006, confirmed that both markers predict outcomes in chronic heart failure but differ in dynamic range and kinetics, reinforcing the importance of knowing which assay was used when interpreting any result.

Why BNP Is Clinically Important

The clinical significance of BNP as a cardiac biomarker rests on two properties: its sensitivity for detecting cardiac stress and its prognostic value for predicting outcomes. Daniels and Maisel, in a 2007 state-of-the-art review in the Journal of the American College of Cardiology, reviewed the diagnostic, prognostic, and therapeutic monitoring applications of natriuretic peptides, establishing the framework that guides their use across clinical settings.

Rule-out value in acute dyspnea

In patients presenting with acute shortness of breath, a very low BNP result makes heart failure an unlikely cause of the symptom — a clinically valuable negative predictor. Maisel, in a widely cited 2003 review in Heart Failure Reviews, reviewed the diagnostic role of BNP in acute congestive heart failure, establishing the 100 pg/mL rule-out threshold and the strong negative predictive value of a low BNP for excluding heart failure as the cause of dyspnea.

Population-level screening evidence

Vasan and colleagues, in the Framingham Heart Study analysis published in JAMA in 2002, showed that plasma natriuretic peptides can serve as potential community screening tools for left ventricular hypertrophy and systolic dysfunction in a general population, providing population-level evidence for their use beyond acute clinical settings. Tsutsui and colleagues, in a 2023 joint scientific statement from the Heart Failure Association of the ESC, the Heart Failure Society of America, and the Japanese Heart Failure Society, consolidated international consensus on the role of natriuretic peptides in heart failure diagnosis and management, representing the current cross-society position on how these markers should be used.

Factors That Affect BNP Results

Many factors beyond cardiac disease can influence BNP and NT-proBNP concentrations. Understanding these confounders is essential for accurate interpretation.

• Age — Raises levels: BNP and NT-proBNP increase progressively with age even without cardiac disease. Age-specific reference ranges are clinically important and used in the ICON age-stratified NT-proBNP thresholds.
• Female sex — Raises levels: Women have higher BNP and NT-proBNP values than men across all age groups. Wang and colleagues, in a 2002 study in the American Journal of Cardiology, documented age and sex effects on plasma natriuretic peptide levels in healthy adults. Proposed mechanism involves estrogen effects on natriuretic peptide clearance.
• Obesity (BMI above 30) — Lowers levels: Adipose tissue expresses NPR-C clearance receptors and clears natriuretic peptides, producing falsely reassuring values in patients with obesity. Wang and colleagues, in a 2004 Circulation paper, documented the inverse relationship between BMI and BNP levels. A normal or low BNP in a person with obesity and cardiac symptoms should not be interpreted as ruling out cardiac stress.
• Renal impairment — Raises NT-proBNP more than BNP: Impaired renal clearance prolongs the half-life of NT-proBNP in particular. Interpret with eGFR context.
• Sacubitril/valsartan — Raises BNP, lowers NT-proBNP: Neprilysin inhibition by sacubitril blocks BNP degradation, making BNP an unreliable monitoring marker in patients on this medication. NT-proBNP is the preferred monitoring marker in treated heart failure patients.
• Atrial fibrillation — Raises levels: Atrial stretch from AF increases natriuretic peptide secretion independent of ventricular dysfunction.
• Acute pulmonary embolism — Raises levels: Right ventricular strain from PE elevates BNP independent of left heart function.
• Critical illness and sepsis — May raise levels: Non-cardiac mechanisms including cytokine-mediated cardiac stress can elevate BNP in the critically ill without primary cardiac disease.

How BNP Testing Works

What type of sample is used

BNP is measured from EDTA plasma collected in a purple-top (K2EDTA) tube. NT-proBNP can be measured from serum or plasma depending on the assay platform. The two assays use different antibody configurations and analytical methods — a BNP result and an NT-proBNP result are not interchangeable. Panagopoulou and colleagues, in a 2013 review in Current Topics in Medicinal Chemistry, reviewed NT-proBNP assay characteristics and clinical interpretation across cardiac disease settings.

Fasting requirements

Fasting is not required for BNP or NT-proBNP testing. Both reflect cardiac wall stress, which is not acutely altered by meal composition or timing.

Timing and specimen stability

BNP is relatively unstable at room temperature and should be processed within two to four hours of collection for accurate results. NT-proBNP is more stable and can tolerate longer transport times. Neither marker varies substantially by time of day under stable clinical conditions, though vigorous exercise immediately before blood draw may transiently affect levels. Results are typically available within hours in most laboratory settings.

Which Biomarkers Are Worth Testing Alongside BNP

BNP and NT-proBNP are most informative when paired with complementary markers that provide mechanistic context. No single cardiac biomarker tells the complete story.

• Troponin (I or T): Marker of myocardial cell injury or death. Troponin testing alongside BNP helps distinguish cardiac wall stress from active myocardial damage — two processes that often co-occur in acute presentations but require different clinical responses.
• hs-CRP: Systemic inflammatory marker. Inflammation is a driver of cardiac remodeling and heart failure progression. An elevated hs-CRP alongside elevated BNP provides additional context about the inflammatory contribution to cardiovascular risk.
• Creatinine and eGFR: Renal function directly affects NT-proBNP clearance. A creatinine measurement alongside NT-proBNP is essential for accurate interpretation, particularly in older patients or those with known kidney disease.
• Lipid panel: Atherosclerotic cardiovascular disease is the leading cause of ventricular dysfunction. A comprehensive lipid panel provides context for the underlying cardiovascular risk driving elevated BNP.

When to Take This Seriously

A single elevated BNP result is not a diagnosis of heart failure. Elevated values appear in older adults, individuals with obesity, people with kidney disease, and those with atrial fibrillation for reasons unrelated to primary ventricular dysfunction. What warrants prompt provider evaluation is an elevated BNP in the context of symptoms: shortness of breath, leg swelling, fatigue with exertion, or reduced exercise tolerance. An isolated mildly elevated BNP in an asymptomatic individual over 70 is common and requires different interpretation than the same value in a 45-year-old with acute dyspnea. A BNP result meaningfully above the rule-in threshold — particularly if NT-proBNP was also measured and is elevated — generally prompts echocardiographic evaluation. Results in the "gray zone" between rule-out and rule-in thresholds are the most clinically complex and most clearly require provider interpretation in the context of the full clinical picture.

The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, published by McDonagh and colleagues in the European Heart Journal, codify when elevated BNP or NT-proBNP warrants echocardiography and cardiac referral — these are the current clinical standard for acting on elevated results in clinical practice.

A BNP or NT-proBNP result is one component of a cardiac evaluation — its meaning is shaped by symptoms, renal function, medications such as sacubitril/valsartan, and other biomarkers measured alongside it. Interpretation should come from the ordering provider in the context of the full clinical picture.

IMPORTANT SAFETY INFORMATION

BNP (brain natriuretic peptide) and NT-proBNP are diagnostic biomarkers used by healthcare providers to evaluate cardiac stress and heart failure. This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. A BNP or NT-proBNP result must be interpreted by a qualified healthcare provider in the context of symptoms, medical history, and other clinical findings.

Reference ranges for BNP and NT-proBNP vary by assay platform, age, sex, and clinical context. The threshold values cited in this article reflect guideline-derived population reference intervals; they are not universal diagnostic cutoffs. A result above any threshold cited here does not establish a diagnosis and should not be acted upon independently of provider evaluation.

Conditions other than heart failure — including kidney disease, pulmonary embolism, atrial fibrillation, obesity, and medications including sacubitril/valsartan — significantly affect natriuretic peptide levels. Result interpretation requires knowledge of these confounders. Consult a qualified healthcare provider for evaluation and interpretation of any laboratory result.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. BNP and NT-proBNP results must be interpreted by a qualified healthcare provider in the context of symptoms, medical history, and other clinical findings. Reference ranges vary by assay and patient characteristics.